Spotlight Series on Hepatitis C


CROI 2015: Panel on Hepatitis C Treatment for Patients Coinfected With HIV (Video)

April 10, 2015

On behalf of IFARA, Liz Highleyman spoke with an international group of doctors about liver-related issues in HIV treatment. Each doctor is involved in a different study related to hepatitis C (HCV), but all agreed on the importance of affordable treatment for the disease. As Dr. Dore put it, "the affordable aspect of therapy is key."

The studies discussed were the ION-4 trial of sofosbuvir/ledipasvir (Harvoni) and the ALLY-2 trial, which combines sofosbuvir (Sovaldi) with daclatasvir. Very high sustained virologic responses of around 96% for a 12-week course of treatment were achieved in both clinical trials.

Historically, hemophiliacs have responded poorly to traditional HCV therapy because their bodies often contain a mixed population of the virus. A recent study showed this subpopulation to respond better to treatment with telaprevir (Incivek), pegylated interferon and ribavirin than to standard therapy.

The importance of treatment access was emphasized by a modeling study, which found that the mortality rate of HIV/HCV coinfected patients doubles, if the treatment of liver-related complications is delayed until the patient's liver disease has reached stage 3.

Two ongoing Australian projects are looking at the impact of a rapid scale-up of HCV treatment on HCV transmission rates. One of the projects is studying a prison population, and the other HIV-positive men who have sex with men.

Linking hard-to-treat populations to care is now one of the most pressing issues besides affordable treatment, Dr. Wyles believed.

Watch the video to learn more:

About the panelists:

  • Kenneth Sherman, M.D., University of Cincinnati, Cincinnati, Ohio
  • Greg Dore, M.D., Kirby Institute, University of New South Wales, Sydney, Australia
  • Cindy Zahnd, M.D., University of Bern, Switzerland
  • David Wyles, M.D., University of California, San Diego, California
  • Susanna Naggie, M.D., Duke University, Durham, North Carolina

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

[CORRECTION 4/16: An earlier version of this article incorrectly identified the two trials that were discussed. We have corrected the names of the trials to ION-4 and ALLY-2 from IL-4 and IL-2.]

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2015 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO. It is a part of the publication The 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015).

Reader Comments:

Comment by: jeniffer (nigeria) Tue., Apr. 14, 2015 at 5:05 pm UTC
I have been HIV positive for 6 years and long for the day to be free of this disease. I would love to be part of any trial that helped find the cure, i have an undetectable viral load and CD4 count of around 1100.
I have tried almost everything but I couldn't find any solution on my disease, despite all these happening to me, i always spend a lot to buy a HIV drugs from hospital and taking some several medications but no relieve, until one day i was just browsing on the
Reply to this comment

Comment by: Opal12 (UK) Sun., Apr. 12, 2015 at 4:12 pm UTC
I think there may be an error in the text above where it refers to the studies presented. The text says Dr David Wyles presented a study IL-2 which used sofosbuvir and Ribavirin and had a success rate of 96%. When I look at the video and at his presentation, the trial he presented is ALLY-2 using sofosbuvir and daclatasvir and that has a success rate of 96%
Reply to this comment

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.